Search Results
Your search for ASCO,ASCO matches 22342 pages
Showing 1 - 50
Christine Lovly, MD, PhD, FASCO, on Adjuvant Selpercatinib in RET Fusion–Positive Early-Stage NSCLC: Expert Perspective
Christine Lovly, MD, PhD, FASCO, of City of Hope, offers her thoughs on the findings of the LIBRETTO-432 trial, which found improved event-free survival with adjuvant selpercatinib after definitive therapy for patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC)...
Elizabeth McDonald, MD, PhD, on GLP-1 Agonists and Breast Cancer Incidence
Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and...
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4...
Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
Daneng Li, MD, on Tegavivint in Advanced HCC
Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015).
Joel W. Neal, MD, PhD, on the CHRYSALIS-2 Study in Atypical EGFR-Mutated Advanced NSCLC
Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previously untreated patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
Music Therapy Noninferior to Cognitive Behavioral Therapy for Anxiety Among Cancer Survivors in Large Telehealth Trial
Guest Editor’s Note: Anxiety is a troubling symptom for many cancer survivors, yet treatment options remain limited. Although cognitive behavioral therapy (CBT) can be beneficial, barriers to access may limit its use. Music therapy, a nonpharmacologic intervention, has been shown to be effective in ...
Hannah L. Kenny, MD, and Joseph M. Curry, MD, on BCC of the Head and Neck: Neoadjuvant Cemiplimab
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515).
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Agarwal et al, the phase III TALAPRO-3 trial has shown improved imaging-based progression-free survival with the addition of talazoparib to enzalutamide in patients receiving androgen-deprivation therapy for...
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Zhou et al, the phase III WU-KONG28 trial has shown that first-line sunvozertinib improved progression-free survival vs chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC)...
Teclistamab in Previously Treated Multiple Myeloma
As reported at the 2026 ASCO Annual Meeting and in The New England Journal of Medicine by Touzeau et al, an interim analysis of the phase III MajesTEC-9 trial has shown improved progression-free survival with teclistamab vs investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd)...
Which Genes Contribute to Early-Onset Breast Cancer in Black Women?
Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer. New research published by Beasley et al in Cancer reveals the genes that are most likely to be mutated to contribute to these increased risks. In the study of 686 Black women diagnosed...
AML: All-Oral Regimen Safe and Eases Treatment Administration Burden
An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine....
Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma
Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508).
Dai Chihara, MD, on a Regimen for Older, Unfit, or Frail Patients With Newly Diagnosed DLBCL
Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed diffuse large ...
Walter Weber, MD, on Implant-Based Breast Reconstruction Techniques After Mastectomy
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss...
Laura Alder, MD, on New Data on Combination Therapy, Immunotherapy, and ADCs in Small Cell Lung Cancer
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of...
Lucy Gilbert, MD, on Overall Survival by Prior Taxane Use in the Phase III ROSELLA Trial
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; ...
Jamie E. Chaft, MD, FASCO, on Nivolumab After Surgery and Adjuvant Chemotherapy in NSCLC
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses findings from ECOG-ACRIN EA5142/ALCHEMIST, a phase III randomized trial that evaluated the efficacy of adjuvant nivolumab after standard-of-care adjuvant therapy in patients with resected lung adenocarcinoma without...
Mohammed Al-Jumayli, MD, on a Digital Prehabilitation Model in Older Adults Undergoing Hepatobiliary Cancer Surgery
Mohammed Al-Jumayli, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the effects of the use of a multimodal, digitally supported prehabilitation program among adults aged 65 years and older undergoing surgery for hepatobiliary cancer; the model was associated with favorable...
William G. Wierda, MD, PhD, on Pirtobrutinib in Treatment-Naive Patients With CLL/SLL
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to bendamustine plus rituximab in treatment-naive patients with chronic lymphocytic leukemia/small...
Lorenza Rimassa, MD, and David James Pinato, MD, PhD, on Expanding the HCC Treatment Landscape: TACE Combinations, Immunotherapies, and Bispecific Antibodies
Lorenza Rimassa, MD, of IRCCS Humanitas Research Hospital, and David James Pinato, MD, PhD, of Imperial College London, discuss positive phase III findings in intermediate-stage hepatocellular carcinoma (HCC) with immunotherapy-based combinations with TACE, second-line data from IMbrave251, and...
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers. The study,...
John V. Heymach, MD, PhD, on First-Line Therapy for Advanced NSCLC With EGFR Exon 20 Insertions
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertinib monotherapy vs platinum-based therapy as first-line treatment for patients with advanced...
Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer...
Mazyar Shadman, MD, on CLL/SLL: Sonorotoclax and Zanubrutinib
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanubrutinib for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma...
Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic Breast Cancer: Maintenance Therapy Comparison
Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).
Elena Elimova, MD, on PD-L1 Subgroup Analysis From HERIZON-GEA-01
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).
Yashasvini Sampathkumar, MD, on Job Retention Intervention for Patients Undergoing Breast Cancer Therapy: Digital vs Print Format
Yashasvini Sampathkumar, MD, of Memorial Sloan Kettering Cancer Center, presents data on Talking to Employers and Medical Staff about Work (TEAMWork), an English/Spanish intervention. The English/Spanish intervention, delivered as a booklet or mobile app, was developed to improve work outcomes...
GLP-1 RAs May Be Associated With Lower Breast Cancer Incidence
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506). The findings were also published in JCO Oncology Practice. “While our...
American Cancer Society Updates Colorectal Cancer Screening Guideline
The American Cancer Society (ACS) recently released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 years and continue through age 75 years for those with a life expectancy greater than...
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response?
A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580). “This is really a cautionary...
Giannis S. Mountzios, MD, on SCLC: Intracranial Effect of Tarlatamab vs Chemotherapy
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib vs observation after complete resection of...
Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC
Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the anti–PD-1 monoclonal antibody budigalimab in patients with relapsed or refractory small cell lung...
Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene...
Marlana M. Orloff, MD, on Metastatic Uveal Melanoma: First-Line Therapy for HLA-A2–Negative Disease
Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choice for first-line therapy among patients with HLA-A2–negative metastatic uveal melanoma (Abstract...
Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer...
Kevin Kalinsky, MD, MS, FASCO, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-04
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-04 trial. The study compared sacituzumab govitecan plus pembrolizumab...
Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal...
Brendan Heiden, MD, on Lung Cancer Screening Eligibility: Smoking Duration vs Pack-Years
Brendan Heiden, MD, of Washington University School of Medicine, discusses data from a unique real-world cohort of nearly 1 million patients in the Veterans Health Administration; researchers evaluated whether tobacco smoking duration improves lung cancer risk prediction compared with tobacco...
Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor...
Misty Dawn Shields, MD, PhD, on SCLC: Expert Point of View
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s meeting. The first focuses on a post hoc analysis of the phase III DeLLphi-304 trial (Abstract 8006),...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared with pembrolizumab alone in patients with high-risk resected melanoma, according to 5-year results...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory...
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with a family history of breast cancer will ultimately develop the disease (Abstract 10545). Although...
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer
Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recurrent endometrial cancer, according to findings presented during the Gynecologic Oncology Session at ...
